Reed Smith and Danish firm Kromann Reumert advised Bavarian Nordic on a licence and supply agreement for approximately $187m to grant its Ebola vaccine exclusively to Johnson & Johnson company Crucell Holland.
The agreement between Danish life sciences company Bavarian Nordic and Johnson & Johnson subsidiary Crucell Holland will see the latter granted an exclusive licence for its multivalent MVA-BN Filovirus vaccine.
Reed Smith London-based life sciences partner John Wilkinson advised on the licensing agreement, and Kromann Reumert partners Michael Pitzner-Bruun and Marianne Philip advised on the supply agreement and transaction, instructed by Bavarian Nordic general counsel Morten Rasmussen and assistant general counsel Troels Winkelmann.
Meanwhile Danish firm Plesner was instructed by Johnson & Johnson for Crucell Holland.
Bavarian Nordic aims to manufacture more than one million doses of the vaccine for 2015 clinic trials and emergency use in the current Ebola outbreak in West Africa.
Background to the deal
Both Reed Smith and Kromann Reumert have been long-standing advisers to Bavarian Nordic. The US firm has been acting for the pharmaceutical company for around six years and Wilkinson is the client relationship partner.
The vaccine deal was announced three days after Reed Smith launched a ‘Global Ebola Task Force’ to “address issues emerging from the spread of the viral disease in West Africa and around the world” and face the challenges that it presents to commerce and trade.
One of the Ebola casualties has been London Mining (17 October 2014), which proved to be the tipping point for the mining giant who went into administration after struggling with debt, collapsing iron ore prices and a dispute with Glencore over payment.